Pfizer announced on November 9th, 2020 that they had cleared the 3rd Phase of clinical trials regarding their new mRNA CV19 vaccine. They reported a 90% therapeutic success rate in protecting the majority of their 43,538 patient volunteers having already received the double dose preventive vaccine. There are only 4,600 volunteers still to receive the...Read More